The N-terminal hexanoyl cap and specific hydrophobic amino acid sequence (Tyr-Ile-Ahx) were engineered specifically to increase lipophilicity and metabolic stability, allowing Dihexa to cross cell membranes and the blood-brain barrier intact in preclinical models
Available documentation may include lot numbers, manufacturing dates, expiration dates, Certificates of Analysis (COAs), and supporting analytical reports depending on the product and batch
Which pharmacy compounds the vial decides whether the molecule matches the label, the concentration is accurate, and the contents are sterile
Once reconstituted, store at 28C and use within 28 days for optimal stability
In contrast, Tirzepatide peptide may work by affecting the patterns linked with GLP and GIP receptors
References Food and Drug Administration